SCHEMBL2167226

SCHEMBL2167226

O=C(O)[C@H](Cc1c[nH]c2ccccc12)NCl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.68
ACE P12821 3/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
KDM4E B2RXH2 2/20 0.65
MAPT P10636 2/20 0.65
APAF1 O14727 1/20 0.65
POLB P06746 1/20 0.65
RECQL P46063 1/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
MEN1 O00255 1/20 0.65
LMNA P02545 1/20 0.65
MPO P05164 1/20 0.65
TSHR P16473 1/20 0.65
BLM P54132 1/20 0.65
PMP22 Q01453 1/20 0.65
KMT2A Q03164 1/20 0.65
HIF1A Q16665 1/20 0.65
ITGB2 P05107 4/20 0.64
ICAM1 P05362 4/20 0.64
ITGAL P20701 4/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1755294 1.00 ALOX15 (0.68) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL30782236 0.90 ALOX15 (0.70) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL170877 0.88 KDM4E (0.69) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL170878 0.88 KDM4E (0.69) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL991035 0.87 KDM4E (0.68) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL17859832 0.87 ALOX15 (0.67) ALOX15ACESMN1; SMN2KDM4EMAPT
Water SCHEMBL5384991 0.87 KDM4E (0.68) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL20816097 0.87 ALOX15 (0.67) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL3857226 0.87 ALOX15 (0.74) ALOX15ACEITGB2ICAM1ITGAL
Abrine SCHEMBL161767 0.87 ALOX15 (0.70) ALOX15ACESMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111511-A2 REVERSIBLY REACTIVE AFFINITY SELECTION MASS SPECTROMETRY AND USES THEREOF CALICO LIFE SCIENCES LLC (US) 2025-05-30 WO claimed
WO-2025109003-A1 P-CADHERIN LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-05-30 WO claimed
US-20240260865-A1 METHOD OF PRODUCING THIN ENZYME-BASED SENSING LAYERS ON PLANAR SENSORS CALIFORNIA INSTITUTE OF TECHNOLOGY 2024-08-08 US claimed
US-11969246-B2 Method of producing thin enzyme-based sensing layers on planar sensors CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2024-04-30 US claimed
CN-117337295-A Bicyclic peptide ligands specific for TREM2 拜斯科技术开发有限公司 2024-01-02 CN claimed
US-20230363672-A1 METHOD OF PRODUCING THIN ENZYME-BASED SENSING LAYERS ON PLANAR SENSORS CALIFORNIA INSTITUTE OF TECHNOLOGY 2023-11-16 US claimed
EP-3350215-A1 CYSTINE KNOT SCAFFOLD PLATFORM H. Hoffnabb-La Roche Ag (CH) 2018-07-25 EP claimed
WO-2017049009-A1 CYSTINE KNOT SCAFFOLD PLATFORM GENENTECH, INC. (US) 2017-03-23 WO claimed
WO-2010017405-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN HELLER ADAM (US) 2010-02-11 WO claimed
EP-2120555-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN Heller, Adam (US) 2009-11-25 EP claimed
US-20080287866-A1 Methods and compositions for the treatment of pain HELLER ADAM 2008-11-20 US claimed
WO-2008094664-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN HELLER ADAM (US) 2008-08-07 WO claimed
US-3991107-A Haloamine transfer NATIONAL PATENT DEVELOPMENT CORPORATION (US) 1976-11-09 US claimed
US-20260071243-A1 BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS UNIV TEXAS (US) 2026-03-12 US disclosed
EP-4110328-B1 INTERVENTION STRATEGY FOR PREVENTION OR TREATMENT OF DIABETES MELLITUS, AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE OR CARDIOVASCULAR DISEASE Stichting Amsterdam UMC (NL) 2026-01-07 EP disclosed
US-20250354108-A1 METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS UNIV DANMARKS TEKNISKE (DK) 2025-11-20 US disclosed
US-3988349-A Salts of N-formyl-6-chlorotryptophan and α-methyl-p-nitrobenzylamine HOFFMANN-LA ROCHE INC. (US) 1976-10-26 US disclosed
US-3965121-A Salts of the γ-lactone of (-)-threo-hydroxycitric acid with R(+)-α-methyl-p-nitrobenzylamine HOFFMANN-LA ROCHE INC. (US) 1976-06-22 US disclosed
US-3965129-A THREO-EPOXYACONITIC ACID BIS-R(+)-ALPHA-METHYL-P-NITROBENZYLAMINE SALT HOFFMANN-LA ROCHE INC. (US) 1976-06-22 US disclosed
US-3943628-A Spoon excavator for applying chemically acting tooth decay attacking fluid KRONMAN JOSEPH H 1976-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287866-A1 Methods and compositions for the treatment of pain ACHE, S100P, P2RX3 ALOX15 442/4885ACE 462/4885SMN1; SMN2 887/4885
US-20260071243-A1 BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS TPH1, TPH2, SLC6A4 ALOX15 3810/4885ACE 3596/4885SMN1; SMN2 4650/4885
US-20250354108-A1 METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS INMT, KARS1, MIA3 ALOX15 25/4885ACE 744/4885SMN1; SMN2 4599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.